Yahoo Finance The Zacks Analyst Blog Highlights Procter & Gamble, AbbVie, The Walt Disney, HSBC Holdings and Duke Energy
For Immediate Release
Chicago, IL – August 25, 2023 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Procter & Gamble Co. PG, AbbVie Inc. ABBV, The Walt Disney Co. DIS, HSBC Holdings plc HSBC and Duke Energy Corp. DUK.
Here are highlights from Thursday’s Analyst Blog:
Top Analyst Reports for Procter & Gamble, AbbVie and Walt Disney
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including The Procter & Gamble Co., AbbVie Inc. and The Walt Disney Co. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today's research reports here >>>
Procter & Gamble shares have outperformed the Zacks Soap and Cleaning Materials industry over the past six months (+11.6% vs. +8.0%). The company continued its robust top and bottom-line surprise trend for the fourth consecutive quarter in the last quarterly release. Also, sales and earnings grew year over year.
Procter & Gamble's organic sales grew, driven by robust pricing and a favorable mix, along with strength across segments. It has been focused on productivity and cost-saving plans to boost margins. Consequently, management has provided an optimistic view for fiscal 2024.
However, the company has been witnessing supply-chain issues, higher SG&A costs, higher transportation costs, geopolitical challenges, currency headwinds and rising inflation. Procter & Gamble's significant international presence exposes it to foreign currency risks, which have been weighing on the company's performance.
(You can read the full research report on Procter & Gamble here >>>)
Shares of AbbVie have gained +9.8% over the past year against the Zacks Large Cap Pharmaceuticals industry's gain of +23.7%. The company has several new drugs in its portfolio with the potential to drive the top line and make up for lost Humira revenues.
Newer products, Skyrizi and Rinvoq, are performing extremely well, bolstered by approval in new indications, which should support top-line growth in the next few years. The company has several early/mid-stage candidates that have blockbuster potential. AbbVie expects several key data readouts in 2023.
However, the company faces several near-term headwinds like Humira loss of exclusivity, increasing competitive pressure on Imbruvica and economic pressure on Juvederm sales. Nonetheless, though revenues are expected to decline in 2023, AbbVie expects to return to robust sales growth in 2025.
(You can read the full research report on AbbVie here >>>)
Shares of Walt Disney have declined -1.2% over the year-to-date period against the Zacks Media Conglomerates industry's decline of -1.4%, reflecting concerns about the profitability of the company's streaming business and the long-term outlook for its media business in the cord-cutting backdrop. Nevertheless, Walt Disney is benefiting from rebounding Parks, Experiences and Products businesses as reflected by the fiscal third quarter results.
Both domestic and international theme parks reported impressive top-line growth. Upcoming attractions like the Frozen theme land at Hong Kong Disneyland and Walt Disney Studios Park in Paris, as well as the Zootopia theme land at Shanghai Disney Resort, are expected to boost the prospects of the theme parks business.
A strong line-up of movies that includes Haunted Mansion, Poor Things and The Creator bodes well for the Media and Entertainment Distribution segment. The company has been nominated for several Emmy awards, which suggests a strong content portfolio.
(You can read the full research report on Walt Disney here >>>)
Other noteworthy reports we are featuring today include HSBC Holdings plc and Duke Energy Corp..
Why Haven't You Looked at Zacks' Top Stocks?
Since 2000, our top stock-picking strategies have blown away the S&P's +6.2 average gain per year. Amazingly, they soared with average gains of +46.4%, +49.5% and +55.2% per year. Today you can access their live picks without cost or obligation.
See Stocks Free >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Duke Energy Corporation (DUK) : Free Stock Analysis Report
Procter & Gamble Company (The) (PG) : Free Stock Analysis Report
The Walt Disney Company (DIS) : Free Stock Analysis Report
AbbVie Inc. (ABBV) : Free Stock Analysis Report
HSBC Holdings plc (HSBC) : Free Stock Analysis Report
